WASHINGTON--(BUSINESS WIRE)--Today Precision Biologics Inc, a Nantworks affiliated clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer, announced the execution of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. The NCI and Precision Biologics, will collaborate on a Phase I clinical study of Precision Biologics Inc.’s second proprietary tumor-associated antigen-derived antibody, NEO-201, in patients with chemo-refractory solid tumors. Preliminary studies have shown that the NEO-201 neo-epitope target is expressed on numerous solid tumors at varying levels. Preclinical studies have demonstrated NEO-201’s ability to destroy cancer cell lines expressing the antigen is by both an immune related mechanism (ADCC) as well as directly through cell apoptosis. In addition, in xenograft murine models, NEO-201 has shown the ability to destroy tumors expressing the NEO-201 antigen.
